Drug induced psoriasis

Acta Dermatovenerologica Croatica

Volumn 19, Issue 1, 2011, Pages 39-42

  Milavec Puretić, Višnja ^a   Mance, Marko ^a   Čeović, Romana ^a   Lipozenčić, Jasna ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Drug eruption; Drug induced psoriasis; Psoriasis

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALEFACEPT; AMOXICILLIN; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CLONIDINE; DICLOFENAC; DIGOXIN; DILTIAZEM; DOXORUBICIN; ELETRIPTAN; ENALAPRIL; ETANERCEPT; GEMFIBROZIL; GLATIRAMER; GOLD SALT; HYDROXYUREA; INTERFERON; IODINE; LITHIUM; MODAFINIL; TACRINE; TETRACYCLINE; UNINDEXED DRUG; VALPROIC ACID; ZALEPLON;

ANTIGEN PRESENTING CELL; AUTOSOMAL DOMINANT INHERITANCE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DISEASE EXACERBATION; GENETIC SUSCEPTIBILITY; HUMAN; MENTAL STRESS; PENETRANCE; PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION;

CHRONIC DISEASE; DRUG ERUPTIONS; FEMALE; HUMANS; INCIDENCE; PHARMACEUTICAL PREPARATIONS; PROGNOSIS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 79955426399     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. McCall O, Lawley T. Eczema, psoriasis, cutaneous infections, acne, and other skin disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 17th ed. New York: McGraw-Hill; 2008. pp. 291-292.
2. http://www.psoriasis.org/netcommunity/sublearn01_faqs
3. Nickoloff BJ, Bonish BK, Marble DJ. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Invest Dermatol Symp Proc 2006;11:16-29.
4. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008;226:132-146.
5. Telfer N, Chalmers R, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.
6. Christophers E, Mrowietz U. Psoriasis. In: Burgdorf WHC, Plewig G, Wolf HH, Landthaler M, eds. Braun Falco's Dermatology. 3rd changed ed. Heidelberg: Springer Medizin Verlag; 2009. pp. 506-526.
7. Gupta M, Gupta A. Psychological factors and psoriasis. In: Grob JJ, Stern R, Mackie R, Weinstock W, eds. Epidemiology, Causes and Prevention of Skin Diseases. Oxford: Blackwell Science; 1997. pp. 129-141.
8. Lindelhof B, Eklund O, Liden S, Stern R. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990;22:1056-1060.
9. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle aged, urban native Swedes. Dermatologica 1986;172:298-304.
10. Abel EA, DiCicco LM, Orfenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007-1022.
11. Litt JZ. Drug Eruption Reference Manual, 12th ed. London, New York: Taylor and Francis; 2006. pp. 643-645.
12. Roujeau JC, Bioulac Sage P, Bourseau C. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991;127:1333-1338.
13. Carr MM. Exanthema and psoriasis. In: Walker R, Edwards C, eds. Clinical Pharmacology and Therapy. Zagreb: Školska knjiga; 2000. pp. 823-836.
14. Van de Kerkhof PCM. Textbook of Psoriasis. Oxford: Blackwell Science; 1999. pp. 8-18.
15. Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB. Angiotensin converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1986;15:1007-1022.
16. Oskay T. Stevens-Johnsons syndrome associated with rampril. Int J Dermatol 2003;42:580-581.
17. Beus A. Paraziti i insekti. In: Francetić I, et al., eds. Farmakoterapijski priručnik. 6th ed. Zagreb: Medicinska naklada; 2010. pp. 623-624.
18. Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, Vinnakota R, Charrow EJ, Forman L. Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther 2009 Dec 19 (Epub ahead of print) doi: 10.1097MJT.0b013e3181c6c0c2.
19. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 2009;102:1133-1140.
20. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J. Cutaneous side effects in patients with rheumatic disease during application of tumor necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-491.
21. Brauchli YB, Jick SS, Curtin F, Meier CR. Lithium, antipsychotics, and risk of psoriasis. J Clin Psychopharmacol 2009;29:134-140.
22. Waqar S, Sarkar P. Exacerbation of psoriasis with β-blocker therapy. Can Med Ass J 2009;181:60.
23. Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am J Ther 2010;17:92-95.
24. Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs. J Rheumatol 2009;83:59-61.
25. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010;340:56-66.
26. Burt CW. National trends in use of medications in office-based practice, 1985-1999. Health Aff (Millwood) 2002;21:206-214.